Elotuzumab(Pfizer)은 Multiple Myeloma 표적 항체로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitors on NK cell-mediated anti-MM effects. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 100% (ClinicalTrials.gov NCT00742560). 차별점: novel preclinical evidence for combining Elo with γδ T cell therapy as a potential treatment strategy for this in.
Multiple Myeloma
Multiple Myeloma
Recruiting
NK cells; however, its direct effect on γδ T cells has
humanized immunoglobulin G1 monoclonal antibody in development for the treatment of patients with multiple my
novel preclinical evidence for combining Elo with γδ T cell therapy as a potential treatment strategy for this in
checkpoint inhibitors on NK cell-mediated anti-MM effects
T cells contribute to tumor eradication but have limited cytotoxicity
biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Elotuzumab(Pfizer)은 Multiple Myeloma 표적 항체로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitors on NK cell-mediated anti-MM effects. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 100% (ClinicalTrials.gov NCT00742560). 차별점: novel preclinical evidence for combining Elo with γδ T cell therapy as a potential treatment strategy for this in.
Multiple Myeloma
Multiple Myeloma
Recruiting
NK cells; however, its direct effect on γδ T cells has
humanized immunoglobulin G1 monoclonal antibody in development for the treatment of patients with multiple my
novel preclinical evidence for combining Elo with γδ T cell therapy as a potential treatment strategy for this in
checkpoint inhibitors on NK cell-mediated anti-MM effects
T cells contribute to tumor eradication but have limited cytotoxicity
biomarkers and biologic profiling to enable optimal, integrated use of mAbs, ADCs, CAR T-cell therapies, and
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.